Clinical characteristics of patients at admission according to age
| . | Age <60 y, n = 340 . | Age ≥60 y, n = 71 . | P . |
|---|---|---|---|
| Clinical characteristics at admission | |||
| Age, y | 38 [28-47] | 74 [69-80] | |
| Male-to-female sex, ratio | 0.51 | 0.38 | |
| Relapsing TTP episode | 30 (9) | 3 (4) | .24 |
| Cerebral involvement | 231 (68) | 56 (79) | .087 |
| Headaches | 120 (35) | 12 (17) | .002 |
| Delirium | 61 (18) | 21 (30) | .034 |
| Seizures | 25 (7) | 11 (15) | .038 |
| Vigilance impairment/coma | 53 (16) | 15 (21) | .29 |
| Focal deficiency | 125 (37) | 34 (48) | .11 |
| Behavior abnormalities | 46 (14) | 17 (24) | .045 |
| Cardiac involvement | 96 (34)* | 23 (37)† | .66 |
| Plasma creatinine, µmol/L | 89 [73; 120] | 124 [89; 198] | <.0001 |
| Abdominal pain | 90 (26) | 8 (11) | .006 |
| Platelet count, ×103/mm3 | 13 [9; 21] | 22 [9; 57] | .002 |
| Hemoglobin level, g/dL | 8 [7; 10] | 9 [8; 11] | .0007 |
| Reticulocyte count, ×103/mm3 | 184 [105; 279]‡ | 143 [77; 339]§ | .92 |
| LDH, fold laboratory higher norm | 4.6 [3; 7]|| | 4.2 [3; 7]§ | .52 |
| Schistocytes, % | 4 [2; 7]¶ | 2.7 [1; 6]§ | .095 |
| Anti-ADAMTS-13 antibody titers, UI/L | 82 [42; 100]* | 90 [36; 100]§ | .81 |
| Troponin level, ng/mL | 0.26 [0.02; 1]‡ | 0.85 [0.1; 4]# | .025 |
| General comorbidities | |||
| Charlson comorbidity score | 0 [0;1] | 2 [0;3] | <.0001 |
| Diabetes mellitus | 13 (4) | 15 (21) | <.0001 |
| Coronary heart disease | 8 (2) | 9 (13) | .0006 |
| Tobacco use | 135 (40) | 15 (22) | .004 |
| Dyslipidemia | 31 (9) | 31 (44) | <.0001 |
| Hypertension | 40 (12) | 46 (65) | <.0001 |
| Chronic kidney disease | 8 (2) | 7 (10) | .006 |
| Transient stroke/stroke | 15 (4) | 7 (10) | .077 |
| Cognitive impairment | 5 (1) | 2 (3) | .34 |
| Institutionalization | 1 (0.3) | 0 (0) | 1.00 |
| Antihypertensive treatment | 31 (9) | 43 (61) | <.0001 |
| Antiplatelet therapy | 18 (5) | 24 (34) | <.0001 |
| Vitamin K antagonist | 5 (1) | 7 (10) | .001 |
| iTTP-associated comorbidities | |||
| Cancer | 1 (0.3) | 8 (11) | <.0001 |
| Autoimmune disease | 102 (30) | 12 (17) | .028 |
| Presence of antinuclear antibodies | 150 (44) | 24 (38)** | .34 |
| If so, antinuclear antibody titers | 200 [100; 640] | 320 [80; 640] | .76 |
| Antiphospholipid antibodies | 9 (3) | 2 (3) | .68 |
| Drugs | 11 (3) | 5 (7) | .17 |
| Infection | 62 (18) | 17 (24) | .32 |
| . | Age <60 y, n = 340 . | Age ≥60 y, n = 71 . | P . |
|---|---|---|---|
| Clinical characteristics at admission | |||
| Age, y | 38 [28-47] | 74 [69-80] | |
| Male-to-female sex, ratio | 0.51 | 0.38 | |
| Relapsing TTP episode | 30 (9) | 3 (4) | .24 |
| Cerebral involvement | 231 (68) | 56 (79) | .087 |
| Headaches | 120 (35) | 12 (17) | .002 |
| Delirium | 61 (18) | 21 (30) | .034 |
| Seizures | 25 (7) | 11 (15) | .038 |
| Vigilance impairment/coma | 53 (16) | 15 (21) | .29 |
| Focal deficiency | 125 (37) | 34 (48) | .11 |
| Behavior abnormalities | 46 (14) | 17 (24) | .045 |
| Cardiac involvement | 96 (34)* | 23 (37)† | .66 |
| Plasma creatinine, µmol/L | 89 [73; 120] | 124 [89; 198] | <.0001 |
| Abdominal pain | 90 (26) | 8 (11) | .006 |
| Platelet count, ×103/mm3 | 13 [9; 21] | 22 [9; 57] | .002 |
| Hemoglobin level, g/dL | 8 [7; 10] | 9 [8; 11] | .0007 |
| Reticulocyte count, ×103/mm3 | 184 [105; 279]‡ | 143 [77; 339]§ | .92 |
| LDH, fold laboratory higher norm | 4.6 [3; 7]|| | 4.2 [3; 7]§ | .52 |
| Schistocytes, % | 4 [2; 7]¶ | 2.7 [1; 6]§ | .095 |
| Anti-ADAMTS-13 antibody titers, UI/L | 82 [42; 100]* | 90 [36; 100]§ | .81 |
| Troponin level, ng/mL | 0.26 [0.02; 1]‡ | 0.85 [0.1; 4]# | .025 |
| General comorbidities | |||
| Charlson comorbidity score | 0 [0;1] | 2 [0;3] | <.0001 |
| Diabetes mellitus | 13 (4) | 15 (21) | <.0001 |
| Coronary heart disease | 8 (2) | 9 (13) | .0006 |
| Tobacco use | 135 (40) | 15 (22) | .004 |
| Dyslipidemia | 31 (9) | 31 (44) | <.0001 |
| Hypertension | 40 (12) | 46 (65) | <.0001 |
| Chronic kidney disease | 8 (2) | 7 (10) | .006 |
| Transient stroke/stroke | 15 (4) | 7 (10) | .077 |
| Cognitive impairment | 5 (1) | 2 (3) | .34 |
| Institutionalization | 1 (0.3) | 0 (0) | 1.00 |
| Antihypertensive treatment | 31 (9) | 43 (61) | <.0001 |
| Antiplatelet therapy | 18 (5) | 24 (34) | <.0001 |
| Vitamin K antagonist | 5 (1) | 7 (10) | .001 |
| iTTP-associated comorbidities | |||
| Cancer | 1 (0.3) | 8 (11) | <.0001 |
| Autoimmune disease | 102 (30) | 12 (17) | .028 |
| Presence of antinuclear antibodies | 150 (44) | 24 (38)** | .34 |
| If so, antinuclear antibody titers | 200 [100; 640] | 320 [80; 640] | .76 |
| Antiphospholipid antibodies | 9 (3) | 2 (3) | .68 |
| Drugs | 11 (3) | 5 (7) | .17 |
| Infection | 62 (18) | 17 (24) | .32 |
Data were provided as median [interquartile range] and compared by use of the Mann-Whitney Wilcoxon rank-sum test. Categorical data were summarized as count (%) and compared by use of the χ2 or Fisher tests.
Data were available for 282 patients.
Data were available for 62 patients.
Data were available for 237 patients.
Data were available for 54 patients.
Data were available for 267 patients.
Data were available for 252 patients.
Data were available for 46 patients.
Data were available for 63 patients.